multifunctional antibodies that create immune synapses

Third Arc Bio is focused on developing innovative therapies for solid tumors and inflammatory and immunology (I&I) diseases through the use of multifunctional antibodies. These antibodies are designed to create immune synapses, which are critical for the precise activation or inhibition of T cells. This approach aims to enhance the effectiveness of immune responses against tumors and other diseases, potentially redefining the standard of care in oncology and immunology. The company boasts a highly experienced team with a strong track record in advancing next-generation medicines.

The company has recently secured significant funding, with an oversubscribed $165 million Series A financing round, which will support its mission to deliver superior biologics. This financial backing underscores the confidence in Third Arc Bio's innovative approach and its potential to transform treatment paradigms in the fields of oncology and I&I diseases. By leveraging their expertise and cutting-edge technology, Third Arc Bio is positioned to make substantial contributions to the development of advanced therapeutic options for patients.

United States

Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. The company's drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging two technologies that power a pipeline of high value therapeutics – a solid tumor synergy platform and an I&I platform that offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety.

Third Arc Bio

Company Details